2. Academic Validation
  3. Improving Anticancer Activity of Doxorubicin by 4'- epi-Dehydroxyamination

Improving Anticancer Activity of Doxorubicin by 4'- epi-Dehydroxyamination

  • ACS Med Chem Lett. 2025 Dec 23;17(1):48-53. doi: 10.1021/acsmedchemlett.5c00681.
Anna A Griadunova 1,  Nicholas L Petrone 2,  Madeleine S Maker 1,  Brian Pallares 3,  Trevor Leung 1,  Allison N Shim 1,  Ömer H Yilmaz 4 5,  Jacob M Goldberg 3,  Jonathan Braverman 1,  Fang Wang 2
Affiliations

Affiliations

  • 1 Innovative Genomics Institute, University of California, Berkeley, Berkeley, California 94720, United States.
  • 2 Department of Chemistry, University of Rhode Island, Kingston, Rhode Island 02881, United States.
  • 3 Department of Chemistry, Colgate University, Hamilton, New York 13346, United States.
  • 4 Department of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
  • 5 Department of Pathology, Beth Israel Deaconess Medical Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02215, United States.
PMID: 41531982 DOI: 10.1021/acsmedchemlett.5c00681
Abstract

Efflux pump-mediated multidrug resistance is a common mechanism by which Cancer cells reduce the efficacy of a broad range of small-molecule therapeutics. We discovered that substituting the 4'-hydroxy group of doxorubicina known efflux pump substratewith an epi-amino group results in a new compound, doxorubamine, which exhibits substantially improved activity against drug-sensitive and -resistant Cancer cells and organoids. Mechanistic studies reveal that doxorubamine is a poor substrate of P-glycoprotein, and it thus retains high potency against multidrug-resistant Cancer. This synthetic modification provides a promising strategy for circumventing multidrug resistance beyond conventional approaches that rely on efflux pump inhibition.

Keywords

ABC transporters; P-glycoprotein; anthracyclines; anticancer; doxorubicin; drug efflux; multidrug resistance.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z